RFX6 and posterior cortical atrophy: Crucially, our findings reveal that diminishing RFX6 expression re‐establishes sensitivity to enzalutamide in CRPC cells and tumors that has previously shown resistance, positioning RFX6 as a highly promising biomarker and therapeutic target for PCa treatment (Figure 8h).